

DR. ERIC J. LAWITZ (Orcid ID : 0000-0002-4234-224X)

Article type : Original Paper

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6

Eric Lawitz¹, Edward Gane², Jordan J. Feld³, Maria Buti⁴, Graham R. Foster⁵, Mordechai Rabinovitz⁶, Eduard Burnevich⁷, Helena Katchman⁸, Krzysztof Tomaszewicz⁹, Fred Lahser¹⁰, Beth Jackson¹⁰, Melissa Shaughnessy¹⁰, Stephanie Klopfer¹⁰, Wendy W. Yeh¹⁰, Michael N. Robertson¹⁰, George J. Hanna¹⁰, Eliav Barr¹⁰, Heather L. Platt¹⁰ on behalf of the C-BREEZE-2 Study Investigators

¹Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA; ²Auckland Clinical Studies, Auckland, New Zealand; ³Toronto Centre for Liver Disease, University of Toronto, Toronto, ON, Canada; ⁴Liver Unit Hospital Universitari Vall d'Hebron and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Barcelona, Spain; ⁵Queen Mary University, London, UK; ⁶University of Pittsburgh Medical Center, University of Pittsburgh, PA, USA; ⁷I.M. Sechenov First Moscow State Medical University, Moscow, Russia; ⁸Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; ⁹Medical University of Lublin, Lublin, Poland; ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JVH.13132](https://doi.org/10.1111/JVH.13132)

This article is protected by copyright. All rights reserved

Author for correspondence:

Eric Lawitz

Texas Liver Institute, University of Texas Health

607 Camden Street

San Antonio, TX 78215

USA

E-mail: lawitz@txliver.com

Phone: 210-253-3426

Fax: 210-477-1808

Running title: Ruzasvir/Uprifosbuvir for HCV Infection

These data were presented at The Liver Meeting® 2017; October 20-24, 2017; Washington, DC.

Lawitz E et al. *Hepatology*. 2017;66(suppl):34A-35A.

Target journal: *Journal of Viral Hepatitis*

Word count: 4000 word limit (exc title page, refs, legends); current word count is 3994.

Tables / figures: Limit 6 figures / tables. Current draft has 3 tables and 3 figures.

1 **Acknowledgments**

2 We extend our gratitude to the participants, their families, investigators, and site personnel who
3 participated in these studies. The C-BREEZE-2 Study Investigators were: Stuart C. Gordon, Eric
4 J. Lawitz, Mordechai Rabinovitz, Peter Jerome Ruane, Amandeep Sahota, Norah A. Terrault,
5 Naoky Tsai, Sumodh C. Kalathil, Gautham Reddy, Wayne Ghesquiere, Sergio Borgia, Brian
6 Conway, Jordan Feld, Keith Tsoi, Curtis L. Cooper, Peter Maged Ghali, Alexander James Venn
7 Thompson, Edward Gane, Jose Luis Calleja Panero, Sabela Lens Maria Buti Ferret, Luis
8 Margusino Franinan, Maria de los Angeles Castro Iglesias, Ashley Brown, Kaushik Agarwal,
9 Graham Foster, Matthew Cramp, Eli Zuckerman, Ella Veitsman, Helena Katchman, Michal
10 Cohen, Yoav Lurie, Ziv Ben Ari, Ewa Janczewska, Aleksandra Szymczak, Krzysztof
11 Tomasiewicz, Waldemar Halota, Robert Flisiak, Adam Mahomed, Mark Wayne Sonderup, Zelda
12 Erika Punt, Mpho Klaas Kgomo, David C Bernhardi, Eduard Z. Burnevich, and Svetlana Kizhlo.
13
14 Medical writing assistance was provided by Jennifer M. Kulak, PhD, and Tim Ibbotson, PhD, of
15 ApotheCom (Yardley, PA, USA) and funded by Merck Sharp & Dohme Corp., a subsidiary of
16 Merck & Co., Inc., Kenilworth, NJ, USA.

17
18 **Funding:** Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of
19 Merck & Co., Inc., Kenilworth, NJ, USA

20
21 **Abbreviation List:**

22 AEs - adverse events
23 ALT - alanine aminotransferase
24 APRI - aspartate aminotransferase to platelet ratio index
25 AST - aspartate aminotransferase
26 CI - confidence interval
27 DAAs - direct-acting antiviral agents
28 FAS - full analysis set

29 FW - follow-up week
30 GT - genotype
31 HCV - hepatitis C virus
32 HIV - human immunodeficiency virus
33 LLoQ - lower limit of quantitation
34 NS3/4A - nonstructural protein 3/4A
35 NS5A - nonstructural protein 5A
36 NS5B - nonstructural protein 5B
37 PP - per-protocol
38 RAP - resistance analysis population
39 RAS - resistance-associated substitution
40 SVR – sustained virologic response
41 SVR12 - sustained virologic response at 12 weeks after the completion of study therapy
42 TW - treatment week

43

44 **Abstract**

45 Ruzasvir (MK-8408, an NS5A inhibitor) and uprifosbuvir (MK-3682, a nonstructural protein 5B
46 nucleotide inhibitor) are highly potent direct-acting antiviral agents for the treatment of hepatitis
47 C virus (HCV) infection. A phase III clinical trial evaluating the two-drug combination of
48 ruzasvir 60 mg plus uprifosbuvir 450 mg suggested suboptimal efficacy in certain HCV
49 genotypes (C-BREEZE 1; NCT02759315). The aim of the present study was to evaluate the
50 efficacy and safety of ruzasvir in combination with uprifosbuvir administered at a higher dose
51 than that assessed in the earlier study (C-BREEZE 2: NCT02956629 /Merck protocol PN041).
52 Treatment-naïve or interferon (with or without ribavirin)–experienced participants with or
53 without compensated cirrhosis were enrolled. All participants received ruzasvir

54 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks. The primary objectives were the
55 proportion of participants with HCV RNA <15 IU/mL at 12 weeks after the end of study therapy
56 (SVR12), and safety and tolerability of the study drug. Overall, 282 participants were enrolled.
57 SVR12 (n/N) was 91.3% (42/46) in participants infected with HCV genotype (GT) 1a; GT1b,
58 96.7% (29/30); GT2, 91.5% (43/47); GT3, 73.8% (45/61); GT4, 98.2% (55/56); GT5, 100.0%
59 (18/18); GT6, 90.9% (20/22). Adverse events (AEs) were reported by 61.3% of participants;
60 drug-related AEs were reported by 33.3%. The most frequent ($\geq 5\%$ of participants) drug-related
61 AEs in all participants were fatigue (7.8%) and headache (7.4%). In conclusion, the two-drug
62 combination of ruzasvir 180 mg plus uprifosbuvir 450 mg for 12 weeks was highly effective and
63 well-tolerated in participants infected with HCV GT1, GT2, GT4, GT5, and GT6, with a lower
64 efficacy in GT3-infected persons.

65

66 **Keywords:** hepatitis C virus; clinical trial; genotype; safety; efficacy

67 The development of direct-acting antiviral agents (DAAs) has transformed the treatment
68 of hepatitis C virus (HCV) infection,¹ and pangenotypic regimens are now available that result in
69 high rates of sustained virologic response (SVR) across all HCV genotypes (GT).² Treatment
70 options have transitioned from genotype-specific regimens such as sofosbuvir/ledipasvir,³
71 elbasvir/grazoprevir,⁴ and paritaprevir/ombitasvir/ritonavir/dasabuvir⁵ to pangenotypic regimens
72 such as glecaprevir/pibrentasvir⁶ and sofosbuvir/velpatasvir.⁷ An additional regimen under
73 investigation for pangenotypic activity is the combination of ruzasvir/uprifosbuvir.

74 Ruzasvir (MK-8408) is a potent HCV nonstructural protein 5A (NS5A) complex
75 inhibitor.⁸ In vitro, it retains activity against RASs selected by first-generation NS5A inhibitors
76 in individuals infected with HCV GT1a.⁸ Uprifosbuvir (MK-3682) is a potent HCV NS5B
77 polymerase nucleotide inhibitor with pangenotypic activity in vitro and a high barrier to
78 resistance. The safety and efficacy of ruzasvir, uprifosbuvir, and the nonstructural protein 3/4A
79 protease inhibitor grazoprevir was explored in the phase 2 C-CREST studies (ClinicalTrials.gov
80 numbers NCT02332707 and NCT02332720).⁹⁻¹¹ In these studies, the three-drug regimen of
81 ruzasvir 60 mg and uprifosbuvir 450 mg in combination with grazoprevir 100 mg, with or
82 without ribavirin, demonstrated high efficacy and excellent tolerability in a broad population that
83 included treatment-naïve and prior interferon-experienced, cirrhotic and noncirrhotic

84 participants with HCV GT1-6 infection, and also participants who had experienced virologic
85 relapse after treatment with all-oral DAA regimens.⁹⁻¹¹ Given the high efficacy of
86 ruzasvir/uprifosbuvir/grazoprevir, the relative contribution of grazoprevir was evaluated in a
87 phase II nonrandomized study by evaluating the two-drug regimen of ruzasvir 60 mg and
88 uprifosbuvir 450 mg. Removal of grazoprevir would eliminate drug–drug interactions caused by
89 the NS3/4A protease inhibitor drug class, and would also eliminate concerns regarding hepatic
90 transaminase elevations with the protease inhibitor, thus potentially enabling use of the two-drug
91 regimen in a broader range of populations. In the C-BREEZE 1 study (NCT02759315), ruzasvir
92 60 mg and uprifosbuvir 450 mg was well tolerated but demonstrated lower efficacy for those
93 infected with GT3 and GT6 infection compared with those with GT1, GT2, or GT4 infection.¹² It
94 was hypothesized that a higher dose of ruzasvir might improve the efficacy of this regimen and
95 support a pangenotypic profile. In the present study, we evaluated the efficacy, safety, and
96 tolerability of the combination of ruzasvir 180 mg and uprifosbuvir 450 mg in participants with
97 HCV GT1-GT6 infection.

98

99 **METHODS**

100 *Study Design*

101 This was a phase II, nonrandomized, open-label clinical trial (ClinicalTrials.gov
102 identifier, NCT02956629/Merck protocol PN041). The study was conducted in accordance with
103 the Declaration of Helsinki and Good Clinical Practice guidelines. Independent institutional
104 review boards or ethics committees reviewed and approved the protocol and applicable
105 amendments for each institution, and all participants gave written informed consent. All
106 participants received ruzasvir 180 mg (3 × 60 mg capsules) plus uprifosbuvir 450 mg (3 × 150
107 mg tablets) orally once daily as separate medications administered under fasting conditions for
108 12 weeks. Dose modifications were not permitted during the study.

109 After the first 50 participants of any HCV GT were allocated to treatment, allocation was
110 paused to assess general safety and tolerability at treatment week (TW) 4. When general safety
111 and tolerability were assessed to be acceptable, the subsequent 200 participants were allocated to
112 treatment with an overall stratification based on genotype. The first 50 participants were included
113 in the overall treatment allocation target of the trial.

114

115 *Participants*

116 Adults aged ≥ 18 years with chronic HCV GT1-6 infection were enrolled. Participants were either
117 treatment-naive or had experienced virologic failure following treatment with an interferon-
118 containing treatment regimen. Participants with fibrosis stage F0-F4 were eligible; cirrhosis was
119 defined as a liver biopsy study consistent with METAVIR F4, FibroScan[®] performed within 12
120 months with a result of >12.5 kPa, or a FibroSure[®] (FibroTest[®]) performed during screening
121 with a score of >0.75 and an aspartate aminotransferase (AST) to platelet ratio index (APRI) of
122 >2 . Among those infected with HCV GT1-GT4, the allocation target was 25%-30% individuals
123 with cirrhosis. Participants could also be either HCV-monoinfected or coinfecting with HCV and
124 human immunodeficiency virus (HIV). Participants receiving HIV medications other than
125 tenofovir, abacavir, lamivudine, emtricitabine, raltegravir, dolutegravir, or rilpivirine were
126 excluded.

127 Participants who had previously received a DAA-based treatment regimen, with hepatitis
128 B virus coinfection (defined as hepatitis B surface antigen–positive), with evidence of
129 decompensated liver disease (presence or history of ascites, esophageal or gastric variceal
130 bleeding, hepatic encephalopathy), with Child-Pugh class B or C cirrhosis (a Child-Pugh-
131 Turcotte score >6), or with evidence of hepatocellular carcinoma were excluded. Participants
132 with alanine aminotransferase (ALT) or AST $>10\times$ upper limit of normal, hemoglobin <10 g/dL,
133 platelets $<50 \times 10^3/\mu\text{L}$, serum albumin <3.0 g/dL, international normalized ratio >1.7 (unless
134 stable on anticoagulant regimen), or estimated glomerular filtration rate <50 mL/min/1.73 m²
135 were also excluded.

136
137 *End points*

138 The primary efficacy end point was sustained virologic response at 12 weeks after the
139 completion of therapy (SVR12). HCV RNA was assessed using the Roche COBAS[®]
140 AmpliPrep/COBAS[®] TaqMan[®] HCV Test v2.0 with a lower limit of quantitation (LLoQ) <15
141 IU/mL. Virologic relapse was defined as HCV RNA \geq LLoQ following completion of all study
142 therapy, after becoming undetectable at end of treatment. Secondary end points included the
143 proportion of participants with virologic failure.

144

145 Safety and tolerability were assessed through the clinical evaluation of adverse events (AEs),
146 vital signs, physical examinations, electrocardiograms, and standard laboratory safety tests.

147

148 Resistance analyses were conducted in all participants with available sequencing data and a
149 treatment outcome of SVR12 or virologic failure (resistance analysis population; RAP). The
150 prevalence and impact on SVR12 of baseline RASs in the NS5A and NS5B regions were
151 assessed using next-generation sequencing (15% sensitivity threshold). NS5A substitutions at
152 amino acid positions 28, 30, 31, or 93 were assessed in all participants. In addition, NS5A RASs
153 at position 58 were assessed in participants with HCV GT3, GT4, or GT6 infection, and RASs at
154 positions 24 or 62 were assessed in participants with GT3 infection. Regardless of HCV
155 genotype, participants who experienced virologic failure had baseline samples sequenced for
156 NS5A RASs at positions 24, 28, 30, 31, 58, 62, or 93. NS5B substitutions at amino acid
157 positions 159, 239, 282, 316, 320, or 321 were also assessed for all genotypes.

158

159 *Statistics*

160 Planned enrollment was approximately 250 participants, with an allocation target of 50
161 participants with HCV GT1 infection, 50 with GT2 infection, 50 with GT3 infection, 50 with
162 GT4 infection, and 25 each with GT5 and GT6 infection. The sample size was based on practical
163 considerations that enabled a reasonable estimation of the SVR12 for each genotype. The full
164 analysis set (FAS) population included all participants who received at least one dose of study
165 drug; in this study, the safety population is identical to the FAS. The per-protocol (PP)
166 population excluded participants who discontinued treatment for administrative reasons (lost to
167 follow-up, withdrew consent). However, participants who discontinued treatment because of
168 drug-related AEs were included in the PP population and counted as treatment failures, and any
169 participant categorized as a reinfection was considered a success in the PP population. The RAP
170 excluded participants who discontinued for reasons other than virologic failure.

171

172

173 **Results**

174 In total, 329 people were screened, and 282 participants were enrolled between November 2016
175 and June 2017. Most participants were male (55.3%); median age was 51.0 years; 78.4% were

176 white; 27.7% had HCV GT1 infection (GT1a, n=46; GT1b, n=30; GT1-other, n=2); 21.6%
177 (n=61) had GT3 infection; 73.0% had baseline HCV RNA >800,000 IU/mL; 20.6% were
178 cirrhotic; 84.0% were treatment-naive; and 3.9% were HCV/HIV co-infected (**Table 1**). Nearly
179 all participants (273/282, 96.8%) received at least one dose of study medication and completed
180 the follow-up week (FW) 12 visit (**Figure 1**).

181

182 *SVR*

183 The SVR12 rate was 89.7% (n/N=253/282; 95% confidence interval [CI], 85.6%-93.0%) in the
184 FAS population. Twenty-nine participants did not achieve SVR12; of these, 19 experienced
185 virologic relapse, 2 experienced drug-related AEs, 1 had reinfection, and 7 participants
186 discontinued for non-study medication-related reasons. In the PP population, the SVR12 was
187 92.3% (251/272; 88.4%-95.2%) (**Table 2**).

188 The SVR12 rate in participants with HCV GT1a infection was 89.6% (43/48; 95% CI
189 77.3%-96.5%) (**Table 2**). Of the five participants with GT1a infection who failed to achieve
190 SVR12, two discontinued from the trial (one participant withdrew from study medication prior to
191 TW2 owing to an AE of substance abuse, and one participant withdrew from the trial prior to
192 TW4) and three relapsed. Of those who relapsed, two relapsed at FW4 and one relapsed at FW12
193 with GT11 that was categorized as GT1a for the analysis. SVR12 appeared to be unaffected by
194 cirrhosis status, with SVR12 rates of 88.9% (8/9) and 97.1% (33/34) in cirrhotic and non-
195 cirrhotic participants, respectively (**Table 3**; FAS population is summarized in **Supplementary**
196 **Table 1**). SVR12 in participants infected with GT1b infection was 96.7% (29/30; 81.8%-99.9%)
197 (**Table 2**). The only participant with GT1b infection who failed to achieve SVR12 was lost to
198 follow-up at FW4. SVR12 was unaffected by cirrhosis status: 100% (7/7) in cirrhotic participants
199 and 100.0% (22/22) in non-cirrhotic participants, although the number of cirrhotic participants
200 was low (**Table 3**; **Supplementary Table 1**).

201 SVR12 was 91.5% (43/47; 95% CI, 79.6%-97.6 %) in participants with HCV GT2
202 infection (**Table 2**). Among the four participants with GT2 who failed to achieve SVR12, one
203 experienced virologic relapse at FW8. The site reported significant non-compliance with study
204 medication dosing for this participant, who took each dose of medication with food and had
205 confirmed low drug exposure. The other three participants who failed to achieve SVR12 all
206 discontinued from the trial: one discontinued owing to drug-related AEs of insomnia and fatigue

207 prior to TW6, and two were lost to follow-up after FW8. SVR12 was 100% (10/10) in cirrhotic
208 participants and 94.1% (32/34) in non-cirrhotic participants, and was unaffected by baseline
209 HCV RNA (94.1% [16/17] in those with baseline HCV RNA \leq 2,000,000 IU/mL and 96.3%
210 [26/27] in those with baseline HCV RNA $>$ 2,000,000 IU/mL) (**Table 3; Supplementary Table**
211 **1**).

212 SVR12 rates were the lowest in participants with HCV GT3 infection (73.8%; 45/61;
213 95% CI 60.9%-84.2%) (**Table 2**). Of the 16 participants with GT3 infection who failed to
214 achieve SVR12, 1 had evidence of reinfection at FW8 (GT3 at baseline and GT1a at FW8), 1
215 discontinued from the trial owing to a non-drug-related AE of substance abuse prior to TW4,
216 and 14 relapsed (12 by FW4 and 2 by FW8). SVR12 was 68.4% (13/19) in cirrhotic participants
217 with HCV GT3 infection and 80.0% (32/40) in non-cirrhotic participants, and was 91.3% (21/23)
218 in those with baseline HCV RNA \leq 2,000,000 IU/mL and 66.7% (24/36) in those with baseline
219 HCV RNA $>$ 2,000,000 IU/mL (**Table 3; Supplementary Table 1**).

220 The SVR12 rate was 98.2% (55/56; 95% CI, 90.4%-100.0%) in participants with HCV
221 GT4 (**Table 2**). The one participant with HCV GT4 infection who failed to achieve SVR12
222 discontinued study medication owing to a non-drug-related AE of abdominal pain prior to TW6.
223 In the PP population, the SVR12 rate was 100% regardless of cirrhosis status or baseline HCV
224 RNA (**Table 3; Supplementary Table 1**).

225 SVR12 was 100% in participants with HCV GT5 infection (18/18; 95% CI, 84.7%-
226 100.0%) and 90.9% (20/22; 95% CI, 70.8%-98.9%) in those with GT6 infection (**Table 2**). Two
227 participants infected with HCV GT6 failed to achieve SVR12: one relapsed at FW4 and the other
228 discontinued study medication prior to Day 7 because of the drug-related AEs of anxiety and
229 nausea. In participants with GT6 infection, the SVR12 rate was 100% (4/4) in those with
230 cirrhosis and 88.9% (16/18; 65.3%-98.6%) in those without cirrhosis, and 88.9% (8/9) in
231 participants with baseline HCV RNA \leq 2,000,000 IU/mL and 92.3% (12/13) in those with
232 baseline HCV RNA $<$ 2,000,000 IU/mL (**Table 3; Supplementary Table 1**).

233 Compared with SVR12 data for the FAS population, two participants (both with GT6
234 infection) relapsed between FW12 and FW24.

235

236 *Efficacy by baseline NS5A RASs*

237 The prevalence of baseline NS5A RASs varied according to HCV genotype, ranging from 0.0%
238 among those infected with HCV GT5 to 86.4% among those infected with HCV GT2, where the
239 majority of these (32/38) were 31L/M (**Supplementary Table 2**). Among those with GT1a
240 infection, the presence of NS5A RAS impacted efficacy (84.6% [11/13] vs 100.0% [31/31] in
241 those with and without RASs, respectively). (**Figure 2**) When efficacy was evaluated according
242 to RAS position, lower efficacy was observed only in the two participants with GT1a infection
243 who had Y93 baseline RAS; one participant had a single Y93 substitution at baseline and the
244 other had substitutions at Y93 and Q30L.

245
246 Efficacy for participants with GT1b (n=29) and GT4 (n=54) was not impacted by the presence of
247 NS5A RASs; SVR12 was 100.0% regardless of the presence of RASs (**Figure 2**). Similarly,
248 detectable NS5A RASs did not significantly impact efficacy in those with HCV GT2 infection
249 (SVR12 rates were 97.4% [37/38] and 100.0% [6/6] for those with and without RASs,
250 respectively) (**Figure 2**); the one participant who relapsed had baseline NS5A 31M RAS.

251
252 SVR12 rates were lower in participants with HCV GT3 infection and NS5A RASs at baseline
253 compared with those with no RASs at baseline (70% [21/30] vs 86.2% [25/29]) (**Figure 2**). The
254 lower efficacy in GT3-infected participants with baseline RASs was not clearly associated with
255 any specific RAS (**Figure 3**).

256
257 All 18 participants with HCV GT5 infection achieved SVR12 (100%; 18/18); none of these
258 participants had detectable NS5A RASs (**Figure 2**). Finally, the rate of SVR12 was 90.9%
259 (10/11) for those with GT6 infection without detectable NS5A RASs and 100.0% (9/9) for those
260 with detectable substitutions (**Figure 2**).

261 262 *Efficacy by baseline NS5B RASs*

263 The prevalence of baseline NS5B RASs varied among persons in the RAP depending on
264 HCV genotype, ranging from 0.0% among those infected with HCV GT1a, GT3, GT5, or GT6 to
265 24.1% among those infected with GT1b (**Supplementary Table 2**). There was no impact of
266 baseline NS5B RAS on efficacy across genotypes. All participants with baseline NS5B RASs

267 achieved SVR12 (9/9; 100%) compared with 92.9% (234/252) of participants without baseline
268 NS5B RASs.

269

270 *Treatment-emergent RASs*

271 Both of the participants with HCV GT1a infection who relapsed had RASs in the NS5A
272 gene region at baseline; one had substitutions at Y93C, and one at Q30L, H58L, and Y93H. The
273 participant with baseline Y93C had two treatment-emergent substitutions: L31V and Y93H. The
274 other participant had two additional substitutions at failure: the addition of L31V and the further
275 diversity of position 58 (52% L, 46% P). The participant with GT11 infection who relapsed had a
276 baseline R30Q RAS, and an additional treatment-emergent Y93H at failure. The one participant
277 with GT2 infection who experienced virologic failure had a baseline RAS in the *NS5A* gene
278 region at T24A and L31M, and no substitutions in the *NS5B* gene region. These substitutions
279 were also present at failure, and no treatment-emergent RASs were detected. The one participant
280 with HCV GT6e infection who relapsed at FW4 did not have detectable baseline RAS; but had
281 treatment-emergent L31M and T93S at the time of relapse. Among the two other participants
282 with GT6 infection who relapsed at FW24, one was GT6q and one was GT6e; neither had any
283 RASs at NS5A or NS5B at baseline or at the time of relapse.

284 Fourteen participants infected with HCV GT3 had a virologic relapse; 11/14 relapsed by
285 FW4, 2/14 by FW8, and 1 at FW12. Four participants did not have RASs at baseline but had
286 treatment-emergent Y93H at relapse; one of the four also had treatment-emergent S62T. Eight
287 participants had RASs at position S62 at baseline (S62T, n=5; S62M, n=1; S62V, n=1; S62I,
288 n=1); the participant with S62I also had A30S and Y93H at baseline, and one participant with
289 S62T also had a Y93H at baseline. All five participants with S62T at baseline also had S62T at
290 relapse; 3/5 also had treatment-emergent Y93H at relapse, 1/5 had Y93H at baseline and relapse,
291 and 1/5 had treatment-emergent L31F RAS. The participant with A30S, S62I, and Y93H at
292 baseline had the same RASs at relapse. The participant with an S62M RAS at baseline had
293 treatment-emergent S62V/Y93H at relapse, and the participant with S62V at baseline had
294 S62V/Y93H RASs at relapse. The two other participants with GT3 infection who relapsed had
295 A30M/A30K/Y93H and A30K at baseline, and A30K/Y93H and A30K/L31V at relapse (both at
296 FW4).

297 Treatment-emergent NS5B RASs were observed in one participant with HCV GT3
298 infection. This participant did not have any NS5A or NS5B RASs detected at baseline, and
299 experienced virologic failure at FW8 with treatment-emergent Y93H in the *NS5A* gene region
300 and S282T RAS in the *NS5B* gene region; however, no NS5B RASs were detected in this region
301 at FW12 and FW24.

302

303 *Safety*

304 The majority of participants reported at least one AE (173/282; 61.3%); the most common AEs
305 (reported in $\geq 5\%$) were headache (n=33, 11.7%), fatigue (n=29, 10.3%), nausea (n=19, 6.7%),
306 and diarrhea (n=14, 5.0%). Drug-related AEs were reported by 94 participants (33.3%); the most
307 common were fatigue (n=22, 7.8%) and headache (n=21, 7.4%). Seven (2.5%) participants
308 reported 12 serious AEs during the trial (1 each of acute coronary syndrome, diarrhea, abscess
309 limb, cellulitis, sinusitis, fall, rhabdomyolysis, acute kidney injury, increased ammonia level,
310 increased blood creatinine level, decreased glomerular filtration rate, and ovarian cyst), none of
311 which were assessed to be drug-related. Five participants (1.8%) reported AEs leading to
312 discontinuation of study medication, including substance abuse (n=2), anxiety and nausea (n=1),
313 insomnia and fatigue (n=1), and abdominal pain (n=1); two (0.7%) of these were considered
314 drug-related AEs (anxiety and nausea; insomnia and fatigue).

315 Two participants experienced hepatic events of clinical interest, defined as the first
316 instance of ALT or AST >500 IU/L, or ALT or AST $>3\times$ nadir and $>3\times$ the upper limit of
317 normal (ULN) from the initiation of study therapy through the first 14 days of follow-up. One
318 participant had an asymptomatic elevation of AST (153 U/L) at TW4 associated with an elevated
319 creatine phosphokinase level. One participant sustained a fall with resultant rhabdomyolysis that
320 was reported as a serious AE not related to study medication, and the associated elevated ALT
321 met criteria for a hepatic event of clinical interest. This same participant met criteria for a renal
322 event of clinical interest, defined as the first instance of an estimated glomerular filtration rate
323 <50 mL/min/1.73 m² from the initiation of study therapy through 14 days following treatment, or
324 the first instance of serum creatinine grade 2 or higher ($>1.3 \times$ ULN) and elevated from baseline
325 from the initiation of study therapy through 14 days following treatment.

326

327

328 **Discussion**

329 The combination of ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks was generally well
330 tolerated. High efficacy was observed in participants with HCV GT1, GT2, GT4, GT5, and GT6
331 infection, with lower efficacy in those with GT3 infection. Although the number of participants
332 was small, the study results suggest a potential impact of baseline NS5A Y93 RAS in persons
333 with GT1a. Efficacy was not affected by cirrhosis status or RASs in those with GT1b, GT2,
334 GT4, and GT5 infection. Efficacy was lower in participants infected with HCV GT3 regardless
335 of cirrhosis status and was only partially accounted for by baseline NS5A RASs.

336 The C-BREEZE-1 trial of ruzasvir 60 mg plus uprifosbuvir 450 mg did not show
337 pangenotypic activity; SVR12 rates were high among those with HCV GT1a (96%; 52/54),
338 GT1b (100%; 15/15), GT2 (97% 28/29), and GT4 infection (90%; 18/20), with lower efficacy in
339 those with GT3 (77%; 33/39) and GT6 infection (67%; 2/3).¹² In the phase II C-CREST trials,
340 the three-drug regimen of ruzasvir 60 mg and uprifosbuvir 450 mg in combination with
341 grazoprevir 100 mg, with or without ribavirin, resulted in SVR12 rates of >90% in a broad
342 patient population with HCV GT1, GT2, GT3, GT4, or GT6 infection.^{9,10} It was hypothesized
343 that a higher dose of ruzasvir might improve pangenotypic activity of the ruzasvir and
344 uprifosbuvir combination and compensate for the lack of NS3/4A inhibition provided by
345 grazoprevir in the C-CREST trials. In the current trial of uprifosbuvir 450 mg and the higher
346 dose of ruzasvir 180 mg, SVR12 rates in the FAS population were not meaningfully higher than
347 those observed with the lower dose of ruzasvir 60 mg in combination with uprifosbuvir.

348 In the current trial, we hypothesized that an increased dose of ruzasvir would overcome
349 the lower efficacy in individuals with HCV GT3 infection observed in C-BREEZE-1.¹²
350 However, we observed that the ruzasvir 180 mg dose used in the present study did not result in
351 higher efficacy in participants with GT3 infection compared with the 60-mg dose of ruzasvir
352 used in C-BREEZE-1 (SVR12 rates of 77% and 73.8%, respectively).¹² It is possible that a
353 plateau was reached on the dose-response curve such that increasing the dose of ruzasvir did not
354 result in any increase in efficacy for GT3 infection. The larger number of participants with GT6
355 infection who were enrolled in C-BREEZE-2 enabled us to more thoroughly evaluate efficacy in
356 this population compared with C-BREEZE-1 (90.9% [20/22] vs 67% [2/3]). Although there was
357 no appreciable difference in SVR12 rates between the lower and the higher ruzasvir doses used

358 in C-BREEZE-1 and C-BREEZE-2, a difference was seen between the ruzasvir plus uprifosbuvir
359 two-drug combination regimen and the ruzasvir-uprifosbuvir-grazoprevir triple-drug regimen
360 evaluated in the C-CREST studies,⁹⁻¹¹ suggesting that for the particular combination of ruzasvir
361 and uprifosbuvir, a third drug is required to ensure a pangenotypic profile. A three-drug
362 combination including uprifosbuvir, grazoprevir, and ruzasvir at the higher dose of 180 mg of
363 ruzasvir has not been evaluated.

364 In the C-BREEZE-1 trial, lower efficacy was observed in cirrhotic participants; 10 of 13
365 participants who relapsed had cirrhosis, including 6 of 9 participants with HCV GT3 infection
366 (67%).¹² Coupled with an analysis of RASs, the data from C-BREEZE-1 suggested that infection
367 with HCV GT1a, GT3, or GT6 in participants who were cirrhotic and/or had baseline RASs was
368 associated with lower SVR rates after treatment with ruzasvir 60 mg plus uprifosbuvir 450 mg.¹²
369 In the current analysis, SVR12 rates in the GT3 subtype were 68.4% (13/19) in cirrhotic
370 participants and 80.0% (32/40) in noncirrhotic participants (PP population). However, 57.1%
371 (8/14) of GT3-infected participants in the PP population with virologic failure were noncirrhotic,
372 suggesting that cirrhosis status may not have as clinically relevant an impact on SVR12 as
373 previously hypothesized.

374 Historically, the presence of RASs at baseline has been associated with lower SVR12
375 rates with some DAA regimens. In our trial, all three participants with HCV GT1 infection who
376 experienced virologic failure (GT1a, n=2; GT11, n=1) had baseline RASs (Y93C, Q30L/ Y93H,
377 and R30Q, respectively). Participants with HCV GT3 infection who experienced virologic
378 failure were likely to have NS5A RASs at baseline (71.4%; 10/14) and at relapse (100%; 14/14),
379 which is in contrast to the results of the C-BREEZE-1 trial, where two of nine participants with
380 GT3 infection who relapsed had baseline NS5A RASs.¹² The most common baseline NS5A RAS
381 in GT3-infected participants was at S62 (57.1%; 8/14), and the most common treatment-
382 emergent RAS was Y93H (71.4% 10/14). The presence of Y93H at baseline has previously been
383 shown to impact the efficacy of DAAs, while the double RAS combinations A30K + L31M and
384 A30K + Y93H and the triple combination A30K + L31M + Y93H have been shown to severely
385 impact susceptibility to daclatasvir, velpatasvir, and elbasvir and to modestly impact
386 susceptibility to pibrentasvir.¹³ It has also been shown that S62 substitutions, while not directly
387 impacting the SVR rate achieved with daclatasvir, may modify the effects of other RASs.¹⁴ Of

388 note, 75% (6/8) of HCV GT3–infected participants with baseline S62 RASs had treatment-
389 emergent RASs: five had treatment-emergent Y93H and one had treatment-emergent L31F.
390 While single S62 substitutions cause minimal (0.2 to 20-fold) shifts in the ruzasvir EC₅₀ in vitro,
391 the presence of additional RASs on the same genome can result in substantial potency losses.
392 The combination of S62I/L/T and Y93H in the GT3 replicon conferred potency losses >1000-
393 fold to ruzasvir. Thus, selection of the treatment-emergent RASs in addition to the baseline S62
394 substitutions impacted ruzasvir potency in those virologic failures.

395 Interpretation of this analysis is subject to several limitations. The size of each genotype
396 population was small, limiting the precision of efficacy measures. This is particularly notable for
397 subpopulations with baseline RASs. The study also had limited enrollment of potentially
398 important subpopulations, such as black participants and those co-infected with HCV/HIV.
399 Finally, there was no direct comparison to either standard-of-care DAA regimens nor to ruzasvir
400 60 mg plus uprifosbuvir 450 mg in the same trial.

401 In conclusion, data from the present study indicate that the combination of ruzasvir 180
402 mg plus uprifosbuvir 450 mg once daily for 12 weeks was well tolerated overall but was
403 suboptimal as a pangenotypic regimen.

404

405 **Statement of Interests**

406 **Conflict of Interests:** This study was funded by Merck Sharp & Dohme Corp., a subsidiary of
407 Merck & Co., Inc., Kenilworth, NJ, USA (MSD).

408 Eric Lawitz reports grants from MSD, AbbVie, and Gilead and personal fees from AbbVie and
409 Gilead.

410 Edward J. Gane has received personal fees as a member of the clinical advisory board for MSD,
411 Gilead Sciences, and AbbVie and has received personal fees as a member of the speakers bureau
412 for Gilead Sciences and AbbVie.

413 Jordan J. Feld has received grant and personal fees for consultant and advisory board work for
414 AbbVie, Janssen, Gilead, and MSD; consultant personal fees from Contravir and Enanta; and
415 grant fees from Wako.

416 Maria Buti has received personal fees from MSD, Gilead, and AbbVie.
417 Graham R. Foster has received grant and personal fees from MSD, Gilead, and AbbVie.
418 Krzysztof Tomaszewicz has received grants, personal fees, and non-financial support from
419 Gilead, AbbVie, and BMS and personal fees and non-financial support from MSD.
420 Frederick Lahser, Beth Jackson, Stephanie Klopfer, Melissa Shaughnessy, Wendy W. Yeh,
421 Michael N. Robertson, George J. Hanna, Eliav Barr, and Heather Platt are employees of MSD.
422 Stephanie Klopfer, Melissa Shaughnessy, Wendy W. Yeh, Michael N. Robertson, George J.
423 Hanna, Eliav Barr, and Heather Platt may own stock in Merck & Co., Inc., Kenilworth, NJ,
424 USA.
425 The following authors have nothing to disclose: Mordechai Rabinovitz, Eduard Z. Burnevich,
426 Helena Katchman.

427

428 **Author Contributions**

429 Eric Lawitz contributed to the acquisition of the data, interpretation of the results, and critically
430 reviewing and revising the manuscript for important intellectual content. Edward Gane
431 contributed to the acquisition of the data, interpretation of the results, and critically reviewing
432 and revising the manuscript for important intellectual content. Jordan J. Feld contributed to the
433 conception, design, and planning of the study, interpretation of the results, and critically
434 reviewing and revising the manuscript for important intellectual content. Maria Buti contributed
435 to the acquisition of the data, analysis of the data, interpretation of the results, drafting of the
436 manuscript, and critically reviewing and revising the manuscript for important intellectual
437 content. Graham R. Foster contributed to the conception, design, and planning of the study,
438 acquisition of the data, analysis of the data, interpretation of the results, and critically reviewing
439 and revising the manuscript for important intellectual content. Mordechai Rabinovitz contributed
440 to the acquisition of the data and critically reviewing and revising the manuscript for important
441 intellectual content. Eduard Burnevich contributed to the acquisition of the data and critically
442 reviewing and revising the manuscript for important intellectual content. Helena Katchman
443 contributed to the acquisition of the data and drafting of the manuscript. Krzysztof Tomaszewicz

444 contributed to the acquisition of the data and critically reviewing and revising the manuscript for
445 important intellectual content. Fred Lahser contributed to the interpretation of the results and
446 critically reviewing and revising the manuscript for important intellectual content. Beth Jackson
447 contributed to the conception, design, and planning of the study, analysis of the data,
448 interpretation of the results, and drafting of the manuscript. Melissa Shaughnessy contributed to
449 the conception, design, and planning of the study, acquisition of the data, analysis of the data,
450 and critically reviewing and revising the manuscript for important intellectual content. Stephanie
451 Klopfer contributed to the conception, design, and planning of the study, analysis of the data,
452 interpretation of the results, and critically reviewing and revising the manuscript for important
453 intellectual content. Wendy W. Yeh contributed to the conception, design, and planning of the
454 study, interpretation of the results, drafting of the manuscript, and critically reviewing and
455 revising the manuscript for important intellectual content. Michael N. Robertson contributed to
456 the conception, design, and planning of the study, interpretation of the results, and critically
457 reviewing and revising the manuscript for important intellectual content. George J. Hanna
458 contributed to the analysis of the data, interpretation of the results, and critically reviewing and
459 revising the manuscript for important intellectual content. Eliav Barr contributed to the
460 conception, design, and planning of the study, analysis of the data, interpretation of the results,
461 drafting of the manuscript, and critically reviewing and revising the manuscript for important
462 intellectual content. Heather L. Platt contributed to the conception, design, and planning of the
463 study, acquisition of the data, analysis of the data, interpretation of the results, drafting of the
464 manuscript, and critically reviewing and revising the manuscript for important intellectual
465 content.

466

467 REFERENCES

- 468 1. American Association for the Study of Liver Diseases, Infectious Diseases Society of
469 America. HCV Guidance: Recommendations for Testing, Managing, and Treating
470 Hepatitis C. Available at: <https://www.hevguidelines.org>. Accessed June 8, 2018.
- 471 2. Jacobson IM. The HCV treatment revolution continues: resistance considerations,
472 pangenotypic efficacy, and advances in challenging populations. *Gastroenterol Hepatol*.
473 2016;12(10 suppl 4):12.
- 474 3. Harvoni [prescribing information]. Foster City, CA: Gilead Sciences Inc.; 2016.

- 475 4. Zepatier [prescribing information]. Kenilworth, NJ: Merck & Co., Inc.; 2018.
- 476 5. Viekira Pak [prescribing information]. North Chicago, IL: AbbVie Inc.; 2018.
- 477 6. Mavyret [prescribing information]. North Chicago, IL: AbbVie Inc.; 2018.
- 478 7. Epclusa [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2017.
- 479 8. Tong L, Yu W, Chen L, et al. The discovery of ruzasvir (MK-8408): a potent, pan-
480 genotype HCV NS5A inhibitor with optimized activity against common resistance-
481 associated polymorphisms. *J Med Chem.* 2017;60(1):290-306.
- 482 9. Gane EJ, Pianko S, Roberts SK, et al. Safety and efficacy of an 8-week regimen of
483 grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus
484 uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1,
485 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label
486 trials. *Lancet Gastroenterol Hepatol.* 2017;2(11):805-813.
- 487 10. Lawitz E, Buti M, Vierling JM, et al. Safety and efficacy of a fixed-dose combination
488 regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in
489 participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3
490 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label
491 trials. *Lancet Gastroenterol Hepatol.* 2017;2(11):814-823.
- 492 11. Wyles D, Wedemeyer H, Ben-Ari Z, et al. Grazoprevir, ruzasvir, and uprifosbuvir for
493 hepatitis C virus after NS5A treatment failure. *Hepatology.* 2017;66(6):1794-1804.
- 494 12. Lawitz E, Poordad F, Anderson L, et al. C-BREEZE 1: efficacy and safety of ruzasvir 60
495 mg plus uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus (HCV)
496 genotype (GT)1, 2, 3, 4, or 6 infection. Presented at: The Liver Meeting® 2017; October
497 20–24, 2017; Washington, DC.
- 498 13. Smith D, Magri A, Bonsall D, et al. Resistance analysis of genotype 3 HCV indicates
499 subtypes inherently resistant to NS5A inhibitors [published online ahead of print,
500 February 9, 2018]. *Hepatology.* doi: 10.1002/hep.29837.
- 501 14. McPhee F, Hernandez D, Zhou N. Effect of minor populations of NS5A and NS5B
502 resistance-associated variants on HCV genotype-3 response to daclatasvir plus
503 sofosbuvir, with or without ribavirin. *Antivir Ther.* 2017;22(3):237-246.

504

505 SUPPORTING INFORMATION

506 Additional Supporting Information may be found online in the supporting information tab for
 507 this article.

508

509

510 **TABLE 1** Baseline patient demographics.

Characteristic	HCV genotype						All participants N=282
	GT1 n=78	GT2 n=47	GT3 n=61	GT4 n=56	GT5 n=18	GT6 n=22	
Sex, n (%)							
Male	43 (55.1)	23 (48.9)	34 (55.7)	33 (58.9)	7 (38.9)	16 (72.7)	156 (55.3)
Female	35 (44.9)	24 (51.1)	27 (44.3)	23 (41.1)	11 (61.1)	6 (27.3)	126 (44.7)
Age, median (range), years	49.5 (19-69)	54.0 (27- 73)	51.0 (26-67)	48.0 (23- 81)	57.5 (29-74)	57.5 (33- 69)	51.0 (19-81)
Race, n (%)							
Asian	2 (2.6)	2 (4.3)	2 (3.3)	0 (0)	1 (5.6)	22 (100.0)	29 (10.3)
Black	4 (5.1)	0 (0)	1 (1.6)	8 (14.3)	9 (50.0)	0 (0)	22 (7.8)
Multiple	1 (1.3)	0 (0)	1 (1.6)	0 (0)	4 (22.2)	0 (0)	6 (2.1)
Native Hawaiian or other Pacific Islander	2 (2.6)	1 (2.1)	0 (0)	1 (1.8)	0 (0)	0 (0)	4 (1.4)
White	69 (88.5)	44 (93.6)	57 (93.4)	47 (83.9)	4 (22.2)	0 (0)	221 (78.4)
Ethnicity, n (%)							
Hispanic/Latino	13 (16.7)	14 (29.8)	12 (19.7)	0 (0)	0 (0)	0 (0)	39 (13.8)

Not Hispanic or Latino	64 (82.1)	32 (68.1)	49 (80.3)	54 (96.4)	18 (100.0)	22 (100.0)	239 (84.8)
Not reported	1 (1.3)	1 (2.1)	0 (0)	2 (3.6)	0 (0)	0 (0)	4 (1.4)
Body-mass index							
kg/m ² , median (range)	26.8 (14.2-42.6)	27.5 (18.9-50.4)	27.4 (17.1-41.6)	25.3 (18.9-35.7)	30.2 (17.3-40.3)	24.8 (17.3-30.1)	26.8 (14.2-50.4)
≥30 kg/m ² , n (%)	22 (28.2)	14 (29.8)	18 (29.5)	11 (19.6)	9 (50.0)	1 (4.5)	75 (26.6)
Baseline HCV RNA, n (%)							
>800,000 IU/mL	59 (75.6)	34 (72.3)	45 (73.8)	39 (69.6)	14 (77.8)	15 (68.2)	206 (73.0)
>2,000,000 IU/mL	44 (56.4)	29 (61.7)	36 (59.0)	24 (42.9)	11 (61.1)	13 (59.1)	157 (55.7)
Cirrhosis, n (%)	17 (21.8)	10 (21.3)	20 (32.8)	6 (10.7)	1 (5.6)	4 (18.2)	58 (20.6)
HCV/HIV co-infected, n (%)	4 (5.1)	1 (2.1)	0 (0)	6 (10.7)	0 (0)	0 (0)	11 (3.9)
Treatment history, n (%)							
Treatment-naive	67 (85.9)	45 (95.7)	52 (85.2)	42 (75.0)	14 (77.8)	17 (77.3)	237 (84.0)
Treatment-experienced	11 (14.1)	2 (4.3)	9 (14.8)	14 (25.0)	4 (22.2)	5 (22.7)	45 (16.0)
<i>IL28B</i> genotype, n (%)							
CC	23 (29.5)	23 (48.9)	24 (39.3)	17 (30.4)	1 (5.6)	16 (72.7)	104 (36.9)
Non-CC	53	24 (51.1)	35	39 (69.6)	17	6 (27.3)	174 (61.7)

	(67.9)		(57.4)		(94.4)		
Unknown	2 (2.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (1.4)

511 GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SD, standard
512 deviation.

513

514

Author Manuscript

TABLE 2 SVR12 in the full analysis set population and the per protocol population.

	HCV genotype							All participants
	GT1a	GT1b	GT2	GT3	GT4	GT5	GT6	
Full analysis set	n=48	n=30	n=47	n=61	n=56	n=18	n=22	N=282
SVR, n/N (%)	43/48 (89.6%)	29/30 (96.7%)	43/47 (91.5%)	45/61 (73.8%)	55/56 (98.2%)	18/18 (100%)	20/22 (90.9%)	253/282 (89.7%)
Non-SVR, n	5	1	4	16	1	0	2	29
Relapse	3	0	1	14	0	0	1	19
Reinfection	0	0	0	1 ^a	0	0	0	1
AE	1	0	0	1	1	0	0	3
DRAE	0	0	1	0	0	0	1	2
LTFU/withdrawn	1	1	2	0	0	0	0	4
Per-protocol analysis	n=45	n=29	n=44	n=59	n=55	n=18	n=22	N=272
Excluded from PP, n	3	1	3	2	1	0	0	10
SVR ^{b,c,d}	1 ^b	0	1 ^c	1 ^d	0	0	0	3
Non-SVR	2	0	2	1	1	0	0	7
AE	1	0	0	1	1	0	0	3
LTFU/withdrawn	1	1	2	0	0	0	0	4
SVR, n/N (%)	42/45 (93.3%)	29/29 (100%)	42/44 (95.5%)	45/59 (76.3%) ^a	55/55 (100%)	18/18 (100%)	20/22 (90.9%)	251/272 (92.3%)
Non-SVR, n	3	0	2	14	0	0	2	21

Relapse	3	0	1	14	0	0	1	19
DRAE	0	0	1	0	0	0	1	2

AE, adverse event. DRAE, drug-related adverse event; GT, genotype; HCV, hepatitis C virus; LTFU, lost to follow-up; PP, per-protocol; SVR, sustained virologic response.

^aOne participant with HCV GT3 infection had evidence of reinfection during follow-up (GT3 at baseline, GT1a at follow-up week 8). This participant was considered as non-SVR within the full analysis set (FAS) analysis but was considered as achieving SVR within the PP analysis.

^bOne participant with HCV GT1a infection withdrew during treatment but continued in the study and had plasma collection 12 weeks after treatment discontinuation; this participant was considered as achieving SVR within the FAS analysis but was excluded from the PP analysis owing to withdrawal from study.

^cOne participant with HCV GT2 infection withdrew during treatment but continued in the study and had plasma collection 12 weeks after treatment discontinuation; this participant was considered as achieving SVR within the FAS analysis but was excluded from the PP analysis due to withdrawal from study.

^dOne participant with HCVGT3 infection withdrew during treatment but continued in the study and had plasma collection 12 weeks after treatment discontinuation; this participant was considered as achieving SVR within the FAS analysis but was excluded from the PP analysis owing to physician decision.

TABLE 3 SVR12 in select subgroups (per-protocol population).

	HCV genotype	
--	--------------	--

	GT1a n=45	GT1b n=29	GT2 n=44	GT3 n=59	GT4 n=55	GT5 n=18	GT6 n=22	All participants N=272
Race, % (n/N)								
White	95.0 (38/40)	100.0 (26/26)	97.6 (40/41)	78.2 (43/55)	100.0 (46/46)	100.0 (4/4)	0	92.9 (197/212)
Black	50.0 (1/2)	100.0 (1/1)	0	0 (0/1)	100.0 (8/8)	100.0 (9/9)	0	90.5 (19/21)
Asian	0	100.0 (2/2)	100.0 (2/2)	50.0 (1/2)	0	100.0 (1/1)	90.9 (20/22)	89.7 (26/29)
Native Hawaiian or other Pacific Islander	100.0 (2/2)	0	0 (0/1)	0	100.0 (1/1)	0	0	75.0 (3/4)
Multiple	100.0 (1/1)	0	0	100.0 (1/1)	0	100.0 (4/4)	0	100.0 (6/6)
Cirrhosis status, % (n/N)								
Cirrhotic	88.9 (8/9)	100.0 (7/7)	100.0 (10/10)	68.4 (13/19)	100.0 (6/6)	100.0 (1/1)	100.0 (4/4)	87.5 (49/56)
Non-cirrhotic	97.1 (33/34)	100.0 (22/22)	94.1 (32/34)	80.0 (32/40)	100.0 (49/49)	100.0 (17/17)	88.9 (16/18)	93.5 (202/216)
Baseline HCV RNA, % (n/N)								

≤800,000 IU/mL	100.0 (10/10)	100.0 (7/7)	91.7 (11/12)	100.0 (15/15)	100.0 (16/16)	100.0 (4/4)	85.7 (6/7)	97.2 (70/72)
>800,000 IU/mL	91.4 (32/35)	100.0 (22/22)	96.9 (31/32)	68.2 (30/44)	100.0 (39/39)	100.0 (14/14)	93.3 (14/15)	90.5 (181/200)
≤2,000,000 IU/mL	100.0 (17/17)	100.0 (13/13)	94.1 (16/17)	91.3 (21/23)	100.0 (31/31)	100.0 (7/7)	88.9 (8/9)	96.6 (115/119)
>2,000,000 IU/mL	89.3 (25/28)	100.0 (16/16)	96.3 (26/27)	66.7 (24/36)	100.0 (24/24)	100.0 (11/11)	92.3 (12/13)	88.9 (136/153)

GT, genotype; HCV, hepatitis C virus.

Author Manuscript

FIGURE 1 Participant disposition by HCV genotype for SVR12.

AE, adverse event; GT, genotype; HCV, hepatitis C virus; LTFU, lost to follow-up; SVR12, sustained virologic response 12 weeks after end of treatment.

^aIncludes all participants who received at least one dose of study medication.


^bIncludes two individuals with HCV GT1-other infection.

FIGURE 2 SVR12 by HCV genotype and presence of baseline NS5A resistance-associated substitutions. Pie charts indicate prevalence of baseline RASs. NS5A substitutions at amino acid positions 28, 30, 31, and 93 were evaluated for all participants with HCV GT1-GT6 infection). In participants with GT3, GT4, GT5, and GT6 infection, NS5A substitutions at position 58 were also evaluated, and additionally, in participants with GT3 infection, substitutions at position 62 were evaluated.


GT, genotype; HCV, hepatitis C virus; NS5A, nonstructural protein 5 A; RAS, resistance-associated substitution; SVR12, sustained virologic response at 12 weeks after completion of therapy.

^aIncludes two participants with HCV GT1-other infection.


FIGURE 3. SVR12 by HCV GT3 genotype and RAS. GT, genotype; HCV, hepatitis C virus; RAS, resistance-associated substitution; SVR12, sustained virologic response at 12 weeks after completion of therapy.



jvh_13132_f1.eps



jvh_13132_f2.eps



jvh_13132_f3.eps